Feasibility and outcome of HCV treatment in a Canadian federal prison population

被引:43
作者
Farley, J
Vasdev, S
Fischer, B
Haydon, E
Rehm, J
Farley, TA
机构
[1] Ctr Addict & Mental Hlth, Toronto, ON M5S 2S1, Canada
[2] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
[3] John Farley Inc, Vancouver, BC, Canada
[4] Univ Ottawa, Ottawa, ON K1N 6N5, Canada
[5] Univ Toronto, Toronto, ON, Canada
[6] Res Inst Addict, Zurich, Switzerland
关键词
D O I
10.2105/AJPH.2004.056150
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 [公共卫生与预防医学]; 120402 [社会医学与卫生事业管理];
摘要
We assessed feasibility and outcome of hepatitis C virus (HCV) treatment in male correctional inmates in British Columbia, Canada. We reviewed the medical charts of 114 treated inmates; 80 had complete data for treatment outcome. Approximately 4 of 5 inmates completed treatment (78.8%); 66.3% achieved sustained virological response. Those who completed treatment, those with injection drug use as a risk factor, and those with genotypes 2 and 3 were significantly more likely to achieve sustained virological response. HCV treatment in correctional inmates is feasible and effective.
引用
收藏
页码:1737 / 1739
页数:3
相关论文
共 20 条
[1]
Treatment of chronic hepatitis C in a state correctional facility [J].
Allen, SA ;
Spaulding, AC ;
Osei, AM ;
Taylor, LE ;
Cabral, AM ;
Rich, JD .
ANNALS OF INTERNAL MEDICINE, 2003, 138 (03) :187-190
[2]
[Anonymous], 2004, Can J Public Health, V95 Suppl 1, pS9
[3]
Prior opiate injection and incarceration history predict injection drug use among inmates [J].
Calzavara, LM ;
Burchell, AN ;
Schlossberg, J ;
Myers, T ;
Escobar, M ;
Wallace, E ;
Major, C ;
Strike', C ;
Millson, M .
ADDICTION, 2003, 98 (09) :1257-1265
[4]
*CAN HIV AIDS LEG, 2002, ACT HIV AIDS PRIS LI
[5]
*CORR SERV CAN, 2003, INF DIS PREV CONTR
[6]
De Prithwish, 2004, Can J Infect Dis Med Microbiol, V15, P221
[7]
Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? [J].
Edlin, BR ;
Seal, KH ;
Lorvick, J ;
Kral, AH ;
Ciccarone, DH ;
Moore, LD ;
Lo, B .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (03) :211-214
[8]
Injection drug use and the hepatitis C virus: Considerations for a targeted treatment approach - The case study of Canada [J].
Fischer, B ;
Haydon, E ;
Rehm, J ;
Krajden, M ;
Reimer, J .
JOURNAL OF URBAN HEALTH-BULLETIN OF THE NEW YORK ACADEMY OF MEDICINE, 2004, 81 (03) :428-447
[9]
Pegylated (40 kDa) interferon alfa-2a (PEGASYS®) in combination with ribavirin:: Efficacy and safety results from a phase III, randomized, actively-controlled, multicenter study [J].
Fried, MW ;
Shiffman, ML ;
Reddy, RK ;
Smith, C ;
Marino, G ;
Goncales, F ;
Haeussinger, D ;
Diago, M ;
Carosi, G ;
Zarski, JP ;
Hoffman, J ;
Yu, J .
GASTROENTEROLOGY, 2001, 120 (05) :A55-A55
[10]
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial [J].
Manns, MP ;
McHutchison, JG ;
Gordon, SC ;
Rustgi, VK ;
Shiffman, M ;
Reindollar, R ;
Goodman, ZD ;
Koury, K ;
Ling, MH ;
Albrecht, JK .
LANCET, 2001, 358 (9286) :958-965